1-2 of 2
Svetislava Vukelja
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine

Joyce O'Shaughnessy, Hartmut Koeppen, Yuanyuan Xiao, Mark R. Lackner, Devchand Paul, Christopher Stokoe, John Pippen, Jr, Lea Krekow, Frankie Ann Holmes, Svetislava Vukelja, Deborah Lindquist, Scot Sedlacek, Ragene Rivera, Robert Brooks, Kristi McIntyre, Carrie Brownstein, Silke Hoersch, Joanne L. Blum, Stephen Jones
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (19): 4305–4311.
https://doi.org/10.1158/1078-0432.CCR-15-0636
Published: 30 September 2015
View article titled, Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Open the PDF for Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Casey Cunningham, Leonard J. Appleman, Miora Kirvan-Visovatti, David P. Ryan, Eileen Regan, Svetislava Vukelja, Peter L. Bonate, Francis Ruvuna, Robert J. Fram, Antti Jekunen, Steve Weitman, Lisa A. Hammond, Joseph P. Eder, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7825–7833.
https://doi.org/10.1158/1078-0432.CCR-05-0058
Published: 08 November 2005
View article titled, Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors in another window